RegMed Investors’ (RMi) pre-open: Weighting what again, the level of conviction

September 3, 2025 7:42am

The sector may be less submissive after gains in the short-term, waving to the near-term while awaiting catalysts that would sustain equity pricings

News: Precigen (PGEN +$0.06 pre-open) has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP. The credit facility provides PGEN with up to $125 M committed across 2 tranches, subject to the terms and conditions of the agreement: The first tranche of $100 M was funded at closing. A second tranche of $25 M can be drawn at PGEN's discretion through 3/31/27.

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

The cell and gene therapy sector has seen a few too many fits and starts, so …

Don’t get too hot but, be bothered by what could be coming! Rate-cut bets face a key test in Friday's jobs report for August, after disappointing inflation data dented stocks last week. Readings on job openings and private payrolls precede the crucial report, while an update on US manufacturing on Tuesday will shed light on the economy.

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Tuesday’s night’s … RMi) Closing Bell: Confidence was skittish … https://www.regmedinvestors.com/articles/14088

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

Wednesday: The pre-open Dow futures are UP +0.01% or (+6 points), the S&P futures are UP +0.49% or (+31 points) and the Nasdaq futures are UP +0.70% or (+163 points)

• Stock futures were moving higher Wednesday, 9/3
• European markets opened and continued cruising higher,
• Asia pacific markets closed mixed.

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Tuesday: The Dow closed DOWN -249.07 points or -0.55%, the S&P closed DOWN -44.72 points or -0.69% while the Nasdaq closed DOWN – 175.922points or -0.82%
• U.S. markets were closed Monday for the Labor Day holiday, global markets did remain open
• Friday: The Dow closed DOWN 92.02- points or -0.20%, the S&P closed DOWN -41.60 points or -0.64% while the Nasdaq closed DOWN -249.608 points or -1.15%
• Last week, the Dow was down 0.2%, the S&P 500 shed 0.1% and Nasdaq lost 0.2%.
• For August, the Dow was up +3%, the S&P +2% and the Nasdaq +1%

Economic Data Docket: Job openings – July, Factory orders – July, Fed Beige Book at 2 pm, Auto sales and 2 St. Fed President speak                                               

Q3 – September, 1 holiday and 1 positive closes

• August - 11 negative and 9 positive closes
• July – 1 market holiday, 13 positive and 9 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Let ‘em ride, I see green after the muddle of red leading up to August’s close, along with the usual ups, downs and just plain uncertainties

As of 9/2/25 – I added to my 35 cell and gene therapy coverage (now 40) and comparable universe: my newbies on Tuesday, now Wedneday ...

• Capricor Therapeutics (CAPR) added +$0.05 with a positive +$0.01 pre-open
• Vertex (VRTX) added +$9.98 with a $2.83 pre-open
• Rocket Therapeutics (RCKT) dipped -$0.04 with a no indication pre-open  
• Arrow Pharmaceuticals (ARWR) added +$3.65 with a negative -0.36 pre-open
• Entrada Therapeutics (TRDA) dipped -$0.09 with a no indication pre-open

The BOTTOM LINE: Certainty rumbled, with uncertainty over Trump tariffs.

• Indexes saw losses on Tuesday, with the Nasdaq nearing its 50-day moving averages before paring losses … as it sank 0.8%, below its 21-day lines but bounced after approaching its 50-day lines.
• The small-cap Russell 2000 gave up 0.6%, but only to its 10-day line.

Those developments could weigh on sentiment to start a new trading month.

• September is historically the worst month for equities, with the S&P 500 averaging a 4.2% drop over the last 5 years, and falling more than 2% on average over the last 10.
• Don’t forget about Fed governor Lisa Cook and her issues of being fired or not

Over the next two weeks, if jobs and inflation data come in solid, concerns could fade quickly and the market likely overtakes that 6500 level. If just ok, that 6500 level likely continues as resistance.

• And finally, if the economic outlook wobbles ahead of the September Fed meeting, we may be entering a choppier stretch.
• One where the market’s “buy the dip” playbook gets tested due to such tight overhead supply to the upside, with much less obvious near-term support to the downside. <Dan Nathen & Guy Adami, RiskReversal Recap >

There's also a case for taking partial profits in stronger names rather than waiting for them to buckle. Investors could choose to make buys in stronger areas, but adding new positions in the current climate carries risks. <IBD>

September is in the front window: understand the “flow”

• 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat of 40 covered
• 9/1 -Monday was a holiday

The previous week of August:

• 8/29 – Friday closed negative with 7 positive, 27 negative and 1 flat
• 8/28 – Thursday closed negative with 15 positive, 17 negative and 3 flats
• 8/27 – Wednesday closed negative with 16 positive, 17 negative and 2 flats
• 8/26 - Tuesday closed positive with 25 positive, 9 negative and 1 flat
• 8/25 – Monday closed negative with 4 positive, 29 negative and 2 flats

Earnings are still the highlight of the week: Meeting earnings expectation and/or missing consensus will deem share pricing outcomes.

• Earnings:  4 net incomes and 25 net losses of 29 releases to date

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.